Corvus Stock: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts (NASDAQ:CRVS)

Corvus' soquelitinib shows potential in atopic dermatitis, with key clinical milestones by 2025. Read here to know why we are bullish on CRVS stock.